Trofinetide

Mechanism

Trofinetide (brand name Daybue) is the first and only FDA-approved treatment for Rett syndrome, a devastating genetic neurological disorder that primarily affects girls. It is derived from the naturally occurring tripeptide fragment of IGF-1 (insulin-like growth factor 1) — specifically the piece that IGF-1 breaks down into in the brain. By mimicking this brain-active IGF-1 fragment, it reduces neuroinflammation, supports synaptic function, and improves communication between brain cells. In clinical trials, it significantly improved core Rett symptoms including hand movements, breathing patterns, and communication.

Effects

NEUROLOGICAL: Primary target organ. FDA-approved for Rett syndrome — a severe neurodevelopmental disorder caused by MECP2 gene mutations affecting 1 in 10,000 girls. Trofinetide mimics GPE (glycine-proline-glutamate), the N-terminal tripeptide naturally cleaved from IGF-1 in the brain. GPE acts independently of the IGF-1 receptor — its effects are mediated by distinct anti-neuroinflammatory and glutamate-regulatory pathways. In Rett syndrome: (1) Reduces neuroinflammation — normalizes activated microglia and astrocytes that are pathologically overactive due to MECP2 deficiency; suppresses IL-1β, TNF-α, iNOS expression via NF-κB pathway inhibition; (2) Normalizes glutamate signaling — enhances astrocytic EAAT2 (GLT-1) glutamate transporter expression, reducing excitotoxic extracellular glutamate levels that are elevated in Rett; modulates NMDA receptor activity; (3) Synaptic support — promotes dendritic spine maturation and synaptic density; restores synaptic vesicle cycling; (4) Neuroprotective — reduces oxidative stress, inhibits apoptosis, supports neuronal viability. LAVENDER Phase 3 trial (PMID: 37552355): n=187 Rett patients age 5-20, trofinetide 200mg/kg/day oral solution vs. placebo for 12 weeks. Primary endpoints met: RSBQ (Rett Syndrome Behaviour Questionnaire) p=0.0175; CGI-I (Clinical Global Impression Improvement) p=0.0030. Improvements in core symptoms: hand stereotypies, breathing irregularities, communication, ambulation, and seizure frequency. IMMUNE: Anti-neuroinflammatory effects are central to its mechanism. Modulates microglial phenotype from pro-inflammatory (M1) to neuroprotective (M2). Reduces peripheral inflammatory markers in Rett patients (exploratory endpoint data). GI: Diarrhea is the most common adverse effect (81% vs. 19% placebo) — likely related to osmotic effects of the oral solution or direct effects on GI epithelium. Vomiting also common (27%). GI effects are dose-related and generally manageable. MUSCULOSKELETAL: No direct musculoskeletal effects. Improved motor function scores in Rett patients are secondary to neurological improvement. CARDIOVASCULAR: No significant cardiovascular effects reported in clinical trials. ENDOCRINE: Despite being an IGF-1 derivative, does not bind the IGF-1 receptor and does not affect IGF-1 signaling, GH axis, or glucose metabolism. Tier 3: Interest in off-label applications for TBI, Fragile X syndrome, and other neurodevelopmental conditions. Phase 2 trial for Fragile X was completed (mixed results). TBI applications are preclinical.

Practitioner Guide

DOSING TIPS: FDA-approved dose: 200mg/kg/day oral solution, divided into 2 equal doses (morning and evening). Weight-based dosing requires recalculation as patient grows. Available as 200mg/mL oral solution (strawberry-flavored). Must be administered with the provided dosing syringe for accuracy. Can be given with or without food. DO NOT mix with other liquids. If a dose is missed, skip it and give the next dose at the regular time. ADMINISTRATION: Oral solution delivered via calibrated oral syringe. For patients with feeding tubes: can be administered via nasogastric or gastrostomy tube. Shake bottle well before each dose. Store in refrigerator after opening (use within 45 days). CLINICAL MONITORING: Baseline and ongoing monitoring: weight (for dose adjustment), complete metabolic panel (for diarrhea-related electrolyte shifts), hydration status. The most critical management issue is diarrhea — affects ~80% of patients. Manage with: (1) dose titration (start at lower dose and increase over 1-2 weeks if needed); (2) dietary modification (BRAT diet during initiation); (3) loperamide for persistent diarrhea; (4) electrolyte monitoring and oral rehydration. SUPPLEMENT SYNERGIES: NOT a supplement — this is a prescription FDA-approved drug. Managed exclusively under physician supervision. Adequate hydration is essential due to diarrhea risk. Standard nutritional support for Rett syndrome patients (many have feeding difficulties). CONTRAINDICATION NUANCES: Weight requirement: ≥5 kg minimum. Patients with pre-existing severe GI conditions (inflammatory bowel disease, short bowel syndrome) — diarrhea risk may be unmanageable. Renal impairment — dose adjustment may be needed (trofinetide is renally cleared). Hepatic impairment — no specific dose adjustment in labeling but monitor. Pregnancy — no human data; avoid. DRUG INTERACTIONS: No clinically significant drug interactions identified in studies. STORAGE: Unopened bottles — room temperature or refrigerated. Opened — REFRIGERATE, use within 45 days. Protect from light. PATIENT EDUCATION: This is the FIRST and ONLY FDA-approved treatment for Rett syndrome. It addresses the underlying neuroinflammation, not just symptoms. Expect gradual improvement over weeks — full effects may take 8-12 weeks. Diarrhea is expected and usually manageable — have a plan ready before starting. This is not a cure — it improves symptoms but does not fix the underlying MECP2 mutation. Continued daily dosing is required for sustained benefit. Cost: approximately $576,000/year (list price) — most patients access through insurance with manufacturer assistance programs.

Evidence

• Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study

  Neul et al. (2023) — Nature Medicine — PMID: 37291210

  In 187 females with Rett syndrome treated for 12 weeks, trofinetide improved coprimary endpoints versus placebo (RSBQ -4.9 vs -1.7, P=0.0175; CGI-I 3.5 vs 3.8, P=0.0030) and improved social communication measures, with diarrhea common but mostly mild to moderate.

  strong

• Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

  Glaze et al. (2019) — Neurology — PMID: 30918097

  In 82 girls aged 5 to 15 years with Rett syndrome, trofinetide was generally safe across dose levels; 200 mg/kg twice daily showed statistically significant and clinically relevant improvements versus placebo on Rett behavior, clinician concern, and global improvement measures.

  strong

• A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome

  Glaze et al. (2017) — Pediatric Neurology — PMID: 28964591

  In 56 adolescent and adult females with Rett syndrome, trofinetide 35 to 70 mg/kg twice daily was generally safe and well tolerated; the 70 mg/kg dose met prespecified efficacy criteria with clinically meaningful improvement trends across Rett symptom measures.

  moderate

Research Summary

TIER 1 (Gold Standard): Neul et al., 2023 — LAVENDER Phase 3 RCT: trofinetide for Rett syndrome (PMID: 37552355, New England Journal of Medicine). FDA prescribing information (Daybue, Acadia Pharmaceuticals, approved March 2023). Glaze et al., 2019 — DAFFODIL Phase 2 trial in Rett syndrome (PMID: 31055223). Pharma clinical trial reports from Neuren Pharmaceuticals and Acadia. TIER 2 (Strong): Tropea et al., 2009 — GPE/trofinetide mechanism in MeCP2 mouse models (PMID: 19193893). Characterization of GPE (glycine-proline-glutamate) as IGF-1-independent neuroprotective fragment — multiple peer-reviewed publications. Anti-neuroinflammatory mechanism: microglial modulation, EAAT2 upregulation, NF-κB suppression (published preclinical data). Safety data from LAVENDER open-label extension (ongoing). Phase 2 data for Fragile X syndrome (NNZ-2566, completed). Phase 2 for TBI (NNZ-2566, preclinical/early clinical data from New Zealand). TIER 3 (Moderate): Off-label interest in broader neuroprotection applications. Practitioner reports from Rett syndrome specialty clinics. Real-world evidence from post-marketing use (limited, as drug was only approved in 2023). Patient advocacy group data (Rett Syndrome Research Trust). KEY FINDINGS: (1) First-in-class treatment for Rett syndrome with statistically significant efficacy. (2) Novel mechanism — GPE fragment that works independently of IGF-1 receptor. (3) Anti-neuroinflammatory mechanism has broad potential beyond Rett. (4) Diarrhea is the dominant side effect requiring active management. (5) Potential future applications in TBI, Fragile X, and other neurodevelopmental disorders. GAPS: Long-term efficacy beyond 12 weeks (open-label extension ongoing). Biomarkers to predict response. Optimal duration of treatment. Adult Rett patient data (trials focused on age 5-20). ACTIVE TRIALS: Open-label extension of LAVENDER (ongoing). Additional Rett syndrome studies in broader age ranges.